A Phase 1 interventional study of Metformin and Oligomeric Procyanidin Complex in Prostate Cancer, sponsored by Medical University of South Carolina. Withdrawn at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-03.
Sponsored by Medical University of South Carolina · Phase 1, Interventional, and Treatment
The overall goal of this study is to identify a safe dose of metformin, in combination with oligomeric procyanidin complex (OPC) for pharmacologic reduction of AGE levels in patients with prostate cancer.
AGEs (advanced glycation endpoints) are a type of metabolite, or substance, found in the food. The AGE content in food is determined by the types of food you eat and also how you prepare your food. The researchers helping conduct this study have found a potential link between AGE levels and cancer. The purpose of this study is to identify safe pharmaceutical agents that can reduce the AGE levels in subjects with advanced cancer.
Subjects must have adequate hematologic, renal, and hepatic function at baseline, as follows:
Exclusion Criteria:
Drug: Metformin · Drug: Oligomeric Procyanidin Complex
Metformin: The starting dose for Metformin is 850mg once a day, the second dose is 850mg once a day; the third dose level is 850mg twice a day; the fourth dose level is 850mg twice a day. Each dose level lasts for 28 days.
OPC: The starting dose for OPC is 500mg once a day; the second dose is 1000mg once a day; the third dose level is 1000mg once a day; the fourth dose level is 1500mg once a day. Each dose level lasts for 28 days.
Also known as: OPC
Maximum tolerated dose (MTD) of metformin in combination with OPC in PCa subjects.
Time frame: 112 days
Correlation between changes to AGE level and changes to PSA.
Time frame: 112 days
Correlation between changes to AGE level and changes to BMI.
Time frame: 112 days
Correlation between changes to AGE level and changes to insulin resistance.
Time frame: 112 days
Correlation between changes to AGE level and changes to A1C.
Time frame: 112 days
Correlations between changes to AGE level and changes to testosterone.
Time frame: 112 days
Correlation between changes to AGE level and changes to diet.
Time frame: 112 days
Correlation between changes to AGE level and changes to quality of life.
FACT-P and AUA questionnaires
Time frame: 112 days
Frequency of adverse events as assessed by CTCAE v. 4
Toxicities will be tabulated by type and grade and the proportion of patients with grade 3, grade 4 or an SAE will be estimated with a 90% confidence interval.
Time frame: 112 days
Correlation between AGE levels and sRAGE (soluble receptor for AGE) expression and signaling.
Time frame: 112 days
Correlation between changes to AGE level and OPC metabolite levels.
Time frame: 112 days
Correlation between changes to AGE level and changes in the stool. microbiome.
Time frame: 112 days
Plan to share: No
No publications or documents are linked to this record.
This study is withdrawn, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of South Carolina